![](/images/Company_Logo/company_logo_default.png)
Editas Medicine Inc Profile last edited on: 6/9/2024
CAGE: 76VR5
UEI: TKSATEM5TEK6
Business Identifier: Novel class of genome editing therapeutics Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
Location Information
Location: Single
Congr. District: 07
County: Middlesex
Congr. District: 07
County: Middlesex
Public Profile
Editas Medicine (NASDAQ:EDIT) is a transformative genome editing company founded by a team experienced in genome editing, protein engineering, and molecular and structural biology, with specific expertise in CRISPR/Cas9 and TALENs technologies. The company is structured around translating its genome editing technology into a novel class of human therapeutics that enable precise and corrective molecular modification to treat the underlying cause of a broad range of diseases at the genetic level. Having substantial patent filings and access to other IP covering foundational genome editing technologies, as well as essential advancements and enablements that will uniquely allow the company to translate early findings into viable human therapeutic products, the firm is tackling translating CRISPR/Cas9 and TALENs technologies into a novel class of human therapeutics that enable precise and corrective molecular modification to treat disease at the genetic level. Following a high number of high-profile publications on CRISPR/Cas9 and TALENs, genome editing has emerged as one of the most exciting new areas of scientific research. These advances have made it possible to modify, in a targeted way, almost any gene in the human body with the ability to directly turn on, turn off or edit disease-causing genes.
Extent of SBIR involvement
Synopsis: Awardee Business Condition
Employee Range
250-500Revenue Range
20M-50MVC funded?
YesPublic/Private
Publicly TradedStock Info
NASDAQ : EDITIP Holdings
150-249Awards Distribution by Agency
Most Recent SBIR Projects
Year | Phase | Agency | Total Amount | |
---|---|---|---|---|
2015 | 1 | NIH | $225,000 | |
Project Title: Vector-Delivered Crispr/Cas as a Cure for Hsv-1-Induced Keratitis |
Key People / Management
Kevin Bitterman -- Interim President. Founder CEO
Katrine S Bosley -- CEO
David Bumcrot -- Senior Director, Molecular and Cell Biology
Clare Carmichael
George M Church -- Founder
Jennifer A Doudna -- CoFounder
Jennifer Franklin
Alexandra Glucksmann -- COO
J Keith Joung -- Co-Founder
Charlene Stern
Feng Zhang -- Founder
Katrine S Bosley -- CEO
David Bumcrot -- Senior Director, Molecular and Cell Biology
Clare Carmichael
George M Church -- Founder
Jennifer A Doudna -- CoFounder
Jennifer Franklin
Alexandra Glucksmann -- COO
J Keith Joung -- Co-Founder
Charlene Stern
Feng Zhang -- Founder